Group 1 - The stock price of Hutchison China MediTech Limited (HCM) increased by 5.03% to $18.15 per share, with a total market capitalization of $3.166 billion as of August 5 [1] - For the fiscal year ending December 31, 2024, the company reported total revenue of $630 million, a decrease of 24.8% year-over-year, and a net profit attributable to shareholders of $37.729 million, down 62.56% year-over-year [1] - The company is scheduled to release its interim report for the fiscal year 2025 on August 7, 2023, before the market opens in the Eastern Time zone [1] Group 2 - Hutchison China MediTech Limited is one of the first innovative pharmaceutical research and development companies in China focused on the global market [2] - Over the past 20 years, the company has established a comprehensive and integrated research and development platform with world-class discovery and development capabilities [2] - The company has successfully launched three self-discovered anti-tumor candidate drugs in China, with the first drug also approved in the United States [2] - Hutchison China MediTech has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [2] - The company is listed on the NASDAQ Global Select Market, Hong Kong Stock Exchange, and AIM market of the London Stock Exchange [2]
和黄医药(US ADR)上涨5.03%，报18.15美元/股，总市值31.66亿美元